Glioblastoma-associated stromal cells (GASCs) from histologically normal surgical margins have a myofibroblast phenotype and angiogenic properties

Journal of Pathology

Volumn 233, Issue 1, 2014, Pages 74-88

  Clavreul, Anne ^a,b,c   Guette, Catherine ^d   Faguer, Rogatien ^c   Tétaud, Clément ^a,b   Boissard, Alice ^d   Lemaire, Laurent ^a,b   Rousseau, Audrey ^c   Avril, Tony ^e   Henry, Cécile ^d   Coqueret, Olivier ^d   Menei, Philippe ^a,b,c  

^a UNIVERSITÉ D'ANGERS   (France)

^b UNIVERSITÉ D'ANGERS   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d CENTRE PAUL PAPIN   (France)

^e CENTRE EUGÈNE MARQUIS   (France)

Author keywords

cancer associated fibroblasts; glioblastoma; peritumoural brain zone; proteomic; target; translational study

Indexed keywords

CYTOKINE; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1;

ADULT; AGED; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CASE REPORT; CELL ISOLATION; CELL MIGRATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MIDDLE AGED; MOUSE; MYOFIBROBLAST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEOMICS; STROMA CELL; TUMOR GROWTH; WOUND HEALING;

CANCER-ASSOCIATED FIBROBLASTS; GLIOBLASTOMA; PERITUMOURAL BRAIN ZONE; PROTEOMIC; TARGET; TRANSLATIONAL STUDY;

BIOPSY; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL COMMUNICATION; CELL SEPARATION; CHEMOKINE CXCL12; COCULTURE TECHNIQUES; FLOW CYTOMETRY; GLIOBLASTOMA; HEPATOCYTE GROWTH FACTOR; HUMANS; MYOFIBROBLASTS; NEOPLASM, RESIDUAL; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; PRIMARY CELL CULTURE; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STROMAL CELLS; TANDEM MASS SPECTROMETRY; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; WOUND HEALING;

EID: 84898600179     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4332     Document Type: Article

References (52)

1. Stupp R, Mason WP, Van den Bent MJ, et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996. (Pubitemid 40349501)
2. Stupp R, Hegi ME, Mason WP, et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
3. De Bonis P, Anile C, Pompucci A, et al., The influence of surgery on recurrence pattern of glioblastoma. Clin Neurol Neurosurg 2013; 115: 37-43.
4. Petrecca K, Guiot M-C, Panet-Raymond V, et al., Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma. J Neurooncol 2013; 111: 19-23.
5. Clavreul A, Etcheverry A, Chassevent A, et al., Isolation of a new cell population in the glioblastoma microenvironment. J Neurooncol 2011; 106: 493-504.
6. Madar S, Goldstein I, Rotter V,. 'Cancer associated fibroblasts'-more than meets the eye. Trends Mol Med 2013; 19: 447-453.
7. Polanska UM, Orimo A,. Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J Cell Physiol 2013; 228: 1651-1657.
8. Servais C, Erez N,. From sentinel cells to inflammatory culprits: cancer-associated fibroblasts in tumour-related inflammation. J Pathol 2013; 229: 198-207.
9. Al-Rakan MA, Colak D, Hendrayani S-F, et al., Breast stromal fibroblasts from histologically normal surgical margins are pro-carcinogenic. J Pathol 2013; 231: 457-465.
10. Louis DN, Ohgaki H, Wiestler OD, et al., The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109. (Pubitemid 47103521)
11. Vindelov LL, Christensen IJ, Nissen NI,. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983; 3: 323-327. (Pubitemid 13087609)
12. Ernoult E, Gamelin E, Guette C,. Improved proteome coverage by using iTRAQ labelling and peptide OFFGEL fractionation. Proteome Sci 2008; 6: 27.
13. Zeeberg BR, Qin H, Narasimhan S, et al., High-throughput GoMiner, an 'industrial-strength' integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of common variable immune deficiency (CVID). BMC Bioinform 2005; 6: 168.
14. Roger M, Clavreul A, Venier-Julienne MC, et al., Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. Biomaterials 2010; 31: 8393-8401.
15. Mullins RD, Hansen SD,. In vitro studies of actin filament and network dynamics. Curr Opin Cell Biol 2013; 25: 6-13.
16. Pollard TD, Cooper JA,. Actin, a central player in cell shape and movement. Science 2009; 326: 1208-1212.
17. Geiger B, Spatz JP, Bershadsky AD,. Environmental sensing through focal adhesions. Nat Rev Mol Cell Biol 2009; 10: 21-33.
18. Balch C, Dedman JR,. Annexins II and V inhibit cell migration. Exp Cell Res 1997; 237: 259-263. (Pubitemid 28027920)
19. Dimberg A, Rylova S, Dieterich LC, et al., αB-crystallin promotes tumor angiogenesis by increasing vascular survival during tube morphogenesis. Blood 2008; 111: 2015-2203.
20. Ruan Q, Han S, Jiang WG, Boulton ME, et al., B-Crystallin, an effector of unfolded protein response, confers anti-VEGF resistance to breast cancer via maintenance of intracrine VEGF in endothelial cells. Mol Cancer Res 2011; 9: 1632-1643.
21. Yamamura H, Hirano N, Koyama H, et al., Loss of smooth muscle calponin results in impaired blood vessel maturation in the tumor-host microenvironment. Cancer Sci 2007; 98: 757-763. (Pubitemid 46563455)
22. Zheng P-P, Severijnen L-A, Van Der Weiden M, et al., A crucial role of caldesmon in vascular development in vivo. Cardiovasc Res 2009; 81: 362-369.
23. Kasper HU, Ebert M, Malfertheiner P, et al., Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density. Virchows Archiv 2001; 438: 116-120. (Pubitemid 32186578)
24. Lin X-D, Chen S-Q, Qi Y-L, et al., Overexpression of thrombospondin-1 in stromal myofibroblasts is associated with tumor growth and nodal metastasis in gastric carcinoma. J Surg Oncol 2012; 106: 94-100.
25. Tang D, Kang R, Zeh HJ, et al., High-mobility group box 1 and cancer. Biochim Biophys Acta 2010; 1799: 131-140.
26. Van Beijnum JR, Nowak-Sliwinska P, Van Den Boezem E, et al., Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene 2013; 32: 363-374.
27. Wang W, Jiang H, Zhu H, et al., Overexpression of high mobility group box 1 and 2 is associated with the progression and angiogenesis of human bladder carcinoma. Oncol Lett 2013; 5: 884-888.
28. Avraham-Davidi I, Ely Y, Pham VN, et al., ApoB-containing lipoproteins regulate angiogenesis by modulating expression of VEGF receptor 1. Nat Med 2012; 18: 967-973.
29. Wang J, Svendsen A, Kmiecik J, et al., Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma. PLoS One 2011; 6: 14.
30. Klingelhöfer J, Grum-Schwensen B, Beck MK, et al., Anti-S100A4 antibody suppresses metastasis formation by blocking stroma cell invasion. Neoplasia 2012; 14: 1260-1268.
31. Kase S, He S, Sonoda S, et al., αB-crystallin regulation of angiogenesis by modulation of VEGF. Blood 2010; 115: 3398-3406.
32. Kang N, Yaqoob U, Geng Z, et al., Focal adhesion assembly in myofibroblasts fosters a microenvironment that promotes tumor growth. Am J Pathol 2010; 177: 1888-1900.
33. Orimo A, Gupta PB, Sgroi DC, et al., Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-348. (Pubitemid 40692295)
34. Granot D, Addadi Y, Kalchenko V, et al., In vivo imaging of the systemic recruitment of fibroblasts to the angiogenic rim of ovarian carcinoma tumors. Cancer Res 2007; 67: 9180-9189. (Pubitemid 47535904)
35. Camphausen K, Purow B, Sproull M, et al., Orthotopic growth of human glioma cells quantitatively and qualitatively influences radiation-induced changes in gene expression. Cancer Res 2005; 65: 10389-10393. (Pubitemid 41743732)
36. Sitohy B, Nagy JA, Dvorak HF,. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 2012; 72: 1909-1914.
37. Gil-Gil MJ, Mesia C, Rey M, et al., Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol 2013; 7: 123-135.
38. Ellis LM, Reardon DA,. Cancer: the nuances of therapy. Nature 2009; 458: 290-292.
39. Takano S., Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation. Brain Tumor Pathol 2012; 29: 73-86.
40. Jahangiri A, De Lay M, Miller LM, et al., Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res 2013; 19: 1773-1783.
41. Lu KV, Bergers G,. Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncol 2013; 2: 49-65.
42. McCarty JH,. Glioblastoma resistance to anti-VEGF therapy: has the challenge been MET? Clin Cancer Res 2013; 19: 1631-1633.
43. Lu KV, Chang JP, Parachoniak CA, et al., VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012; 22: 21-35.
44. Keunen O, Johansson M, Oudin A, et al., Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 2011; 108: 3749-3754.
45. Navis AC, Bourgonje A, Wesseling P, et al., Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2. PLoS One 2013; 8: e58262.
46. Di Tomaso E, Snuderl M, Kamoun WS, et al., Glioblastoma recurrence after cediranib therapy in patients: lack of 'rebound' revascularization as mode of escape. Cancer Res 2011; 71: 19-28.
47. Toussaint LG, Nilson AE, Goble JM, et al., Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion. Mol Cancer 2012; 11: 32.
48. Brunckhorst MK, Wang H, Lu R, et al., Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis. Cancer Res 2010; 70: 7283-7293.
49. Huang D, Ding Y, Zhou M, et al., Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010; 70: 1063-1071.
50. Batchelor TT, Gerstner ER, Emblem KE, et al., Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA 2013; 110: 19059-19064.
51. Welti JC, Gourlaouen M, Powles T, et al., Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene 2011; 30: 1183-1193.
52. Omuro AM,. Exploring multi-targeting strategies for the treatment of gliomas. Curr Opin Invest Drugs 2008; 9: 1287-1295.